-
Vehof J, Snieder H, Jansonius N, et al. Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. Ocul Surf. 2021;19:83-93.
-
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15:334-65.
-
Miyazaki D, Fukagawa K, Okamoto S, et al. Epidemiological aspects of allergic conjunctivitis. Allergol Int. 2020;69:487-95.
-
Kaurstad Morthen M, Magno MS, Utheim TP, et al. The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants. Ocul Surf. 2021;21:107-117.
-
Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15:802-812.
-
Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15:366-403.
-
Knop E, Knop N, Millar T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938-78.
-
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-83.
-
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.
-
Eberhardt M, Rammohan G. Blepharitis. StatPearls. Treasure Island (FL)2021.
-
Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472-8.
-
Hassanzadeh S, Varmaghani M, Zarei-Ghanavati S, et al. Global Prevalence of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis. Ocul Immunol Inflamm. 2021;29:66-75.
-
Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52:1994-2005.
-
Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7:S1-S14.
-
Rim TH, Kang MJ, Choi M, et al. Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study. Clin Exp Ophthalmol. 2017;45:448-54.
-
Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511-38.
-
Wolpert L, Hammond CJ, Vehof J. A hypothesis-free study of medication use and symptomatic dry eye in 79,866 participants. Investigative Ophthalmology & Visual Science. 2018;Vol.59, 958.
-
Morthen MK, Magno MA, Utheim TP, et al. The physical and mental burden of dry eye disease: A large population-based study investigating the relationship with health-related quality of life and its determinants. Ocul Surf. 2021;21:107-117.
-
Magno MS, Utheim TP, Snieder H, et al. The relationship between dry eye and sleep quality. Ocul Surf. 2021;20:13-9.
-
Morthen MK, Magno MS, Utheim TP, et al. The vision-related burden of dry eye. Ocul Surf. 2021;S1542-0124:00124-5.
-
Sivakumar GK, Patel J, Malvankar-Mehta MS, et al. Work productivity among Sjogren's Syndrome and non-Sjogren's dry eye patients: a systematic review and meta-analysis. Eye (Lond). 2021.
-
Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond). 2015;29:301-12.
-
Galor A, Moein HR, Lee C, et al. Neuropathic pain and dry eye. Ocul Surf. 2018;16:31-44.
-
Vehof J, Kozareva D, Hysi PG, et al. Relationship between dry eye symptoms and pain sensitivity. JAMA Ophthalmol. 2013;131:1304-8.
-
Vehof J, Sillevis Smitt-Kamminga N, Kozareva D, et al. Clinical Characteristics of Dry Eye Patients With Chronic Pain Syndromes. Am J Ophthalmol. 2016;162:59-65 e2.
-
Wan KH, Chen LJ, Young AL. Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye (Lond). 2016;30:1558-67.
-
Vehof J, Sillevis Smitt-Kamminga N, Nibourg SA, et al. Predictors of Discordance between Symptoms and Signs in Dry Eye Disease. Ophthalmology. 2017;124:280-6.
-
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539-74.
-
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-21.
-
Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575-628.
-
-
Aktas S, Tetikoglu M, Kocak A, et al. Impact of Smoking on the Ocular Surface, Tear Function, and Tear Osmolarity. Curr Eye Res. 2017:1-5.
-
Bron AJ, Willshire C. Tear Osmolarity in the Diagnosis of Systemic Dehydration and Dry Eye Disease. Diagnostics (Basel). 2021;11.
-
Downie LE, Ng SM, Lindsley KB, et al. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. Cochrane Database Syst Rev. 2019;12:CD011016.
-
Magno MS, Daniel T, Jansonius NJ, et al. The Relationship Between Alcohol Consumption and Dry Eye. Ocul Surf. 2021;21:87-95.
-
Magno M, Moschowits E, Arita DR, et al. Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction. Surv Ophthalmol. 2021.
-
Arita R, Fukuoka S, Mizoguchi T, et al. Multicenter Study of Intense Pulsed Light for Patients with Refractory Aqueous-Deficient Dry Eye Accompanied by Mild Meibomian Gland Dysfunction. J Clin Med. 2020;9.
-
Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020;3:CD013559.
-
Liu S, Tang S, Dong H, et al. Intense pulsed light for the treatment of Meibomian gland dysfunction: A systematic review and meta-analysis. Exp Ther Med. 2020;20:1815-21.
-
Ren X, Chou Y, Wang Y, et al. Comparison of intense pulsed light and near-infrared light in the treatment of dry eye disease: a prospective randomized study. Acta Ophthalmol. 2021.
-
Wladis EJ, Aakalu VK, Foster JA, et al. Intense Pulsed Light for Meibomian Gland Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020;127:1227-33.
-
Yang L, Pazo EE, Zhang Q, et al. Treatment of contact lens related dry eye with intense pulsed light. Cont Lens Anterior Eye. 2021:101449.
-
Van der Westhuizen L, Pucker AD. Over the counter (OTC) artificial tear drops for dry eye syndrome: A Cochrane review summary. Int J Nurs Stud. 2017;71:153-4.
-
Yang YJ, Lee WY, Kim YJ, et al. A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. Int J Environ Res Public Health. 2021;18.
-
Barabino S, Antonelli S, Cimbolini N, et al. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest Ophthalmol Vis Sci. 2014;55:6499-504.
-
Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-34.
-
Jeanen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-9.
-
Erickson S, Sullivan AG, Barabino S, et al. TFOS European ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases. Ocul Surf. 2020.
-
Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79:3-18.
-
Arita R, Fukuoka S. Efficacy of Azithromycin Eyedrops for Individuals With Meibomian Gland Dysfunction-Associated Posterior Blepharitis. Eye Contact Lens. 2021;47:54-9.
-
Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871-7.
-
Hosseini K, Lindstrom RL, Foulks G, et al. A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin-0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitis. Clin Ophthalmol. 2016;10:1495-503.
-
Igami TZ, Holzchuh R, Osaki TH, et al. Oral azithromycin for treatment of posterior blepharitis. Cornea. 2011;30:1145-9.
-
John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. Ann Ophthalmol (Skokie). 2008;40:68-74.
-
Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens. 2012;38:73-9.
-
Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94:200-6.
-
Shah SA, Spencer SK, Tharmarajah B, et al. Meibomian gland dysfunction: azithromycin and objective improvement in outcomes in posterior blepharitis. Clin Exp Ophthalmol. 2016;44:866.
-
Yildiz E, Yenerel NM, Turan-Yardimci A, et al. Comparison of the Clinical Efficacy of Topical and Systemic Azithromycin Treatment for Posterior Blepharitis. J Ocul Pharmacol Ther. 2018;34:365-72.
-
Zandian M, Rahimian N, Soheilifar S. Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis. Int J Ophthalmol. 2016;9:1016-9.
-
Wladis EJ, Bradley EA, Bilyk JR, et al. Oral Antibiotics for Meibomian Gland-Related Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2016;123:492-6.
-
Hoy SM. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. Drugs. 2017;77:1909-16.
-
Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125-31.
-
Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98:1016-22.
-
Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2:CD009327.
-
Cohn GS, Corbett D, Tenen A, et al. Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease. Invest Ophthalmol Vis Sci. 2019;60:147-53.
-
Farhangi M, Cheng AM, Baksh B, et al. Effect of non-invasive intranasal neurostimulation on tear volume, dryness and ocular pain. Br J Ophthalmol. 2020;104:1310-6.
-
Gumus K, Schuetzle KL, Pflugfelder SC. Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation. Am J Ophthalmol. 2017;177:159-68.
-
Pattar GR, Jerkins G, Evans DG, et al. Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment. Ocul Surf. 2020;18:249-57.
-
Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. Clin Ophthalmol. 2018;12:263-70.
-
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121:475-83.
Account
1
